Coronavirus Update - 09th November 2020

We would like to reassure our customers that as England enters its second national lockdown period, we remain open for business and at full capacity as we have done since the start of this pandemic and fully comply with all government guidance on minimising the risks of COVID-19.

As the situation continues to evolve, we will keep all our customers and stakeholders informed of our activities through this web-page which is updated on a regular basis.

Our work and case studies

Challenge: To manufacture drug substance and screen a selection of corresponding pharmaceutically acceptable salt forms.  From the resulting salt forms, choose a candidate which exhibits optimal characteristics for formulation and bioavailability.

Customer:

US Biopharmaceutical

Outcome:

API was manufactured at ARCINOVA and a series of salts subsequently produced.  Each salt form was assessed with respect to salt formation, solubility, hygroscopicity, crystallinity, polymorph tendency, chemical stability and particle size/morphology. An optimal salt form was identified and manufactured at ARCINOVA. 

drug substance Salt Case Study